Gan & Lee Pharmaceuticals and XtalPi Announce Global Strategic Collaboration on AI-Powered Peptide Drug Discovery for Metabolic Diseases

December 9,Gan&Lee PharmaceuticalsGan&Lee Pharmaceuticals Announces R&D Collaboration and AI Technology Platform Licensing Agreement with XtalPi in the Field of Metabolic Diseases for AI-Peptide Innovative Drug Development. According to the agreement, Gan&Lee Pharmaceuticals will utilize XtalPi's proprietary AI-peptide R&D platform, PepiX™, to focus on unmet core therapeutic needs in the field of metabolic diseases, accelerating the discovery and development process of novel peptide innovative drugs.